Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · The Lancet · 2,820 citations
https://doi.org/10.1016/s0140-6736(19)31149-3
H
Harpreet S. Bajaj
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
204
Papers
8.9K
Citations
37
h-index
74
i10-index
Harpreet S. Bajaj is an academic researcher from Çevre, Şehircilik ve İklim Değişikliği Bakanlığı. The author has contributed to research in topics: Diabetes Treatment and Management & Diabetes Management and Research & Metabolism, Diabetes, and Cancer. The author has an h-index of 37, co-authored 174 publications.
ORCID: 0000-0002-1461-1465Papers by this author
worksDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · The Lancet · 600 citations
https://doi.org/10.1016/s0140-6736(19)31150-x
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
2020 · Diabetologia · 70 citations
https://doi.org/10.1007/s00125-019-05080-9
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2025 · New England Journal of Medicine · 49 citations
https://doi.org/10.1056/nejmoa2502082
Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the <scp>ONWARDS</scp> 1–5 trials
2024 · Diabetes Obesity and Metabolism · 16 citations
https://doi.org/10.1111/dom.15726
Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline
2025 · Canadian Journal of Diabetes · 8 citations
https://doi.org/10.1016/j.jcjd.2025.01.004
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat